A quick “gut reset” may help keep weight off after Ozempic.
A new outpatient procedure could help people avoid regaining weight after stopping popular medications like Ozempic and semaglutide, according to research to be presented at Digestive Disease Week (DDW) 2026. Experts estimate that about 70% of people who discontinue these drugs regain much of the weight they lost, often within 18 months. Nearly one in five adults with obesity has used a glucagon-like peptide-1 (GLP-1), underscoring how widespread this issue has become.
First Rigorous Trial Shows Promising Results
The study provides the first blinded, randomized, sham-controlled evidence that a technique called duodenal mucosal resurfacing may offer a safe and effective way to maintain weight loss without continuing medication. The findings suggest it could help people preserve the benefits they achieved while taking drugs like semaglutide.
“As effective as GLP-1 medications are, many people stop taking them because of cost, side effects or simply not wanting to take a drug long-term,” said lead author Shelby Sullivan, MD, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center and professor of medicine, Dartmouth Geisel School of Medicine. “But, if they stop these medications, weight regain occurs in the vast majority of patients, and the metabolic benefits are lost. Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge unmet need. These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance.”
How Duodenal Mucosal Resurfacing Works
Duodenal mucosal resurfacing is an investigational endoscopic procedure that uses controlled heat to remove damaged tissue from the inner lining of the duodenum, the first part of the small intestine just below the stomach. This process ablates (burns) the unhealthy mucosal layer and stimulates the growth of new, healthier tissue.
The REMAIN-1 trial is evaluating whether this renewal of the intestinal lining can trigger a lasting metabolic reset, helping the body maintain weight loss after stopping medications like Ozempic, semaglutide, or tirzepatide.
Trial Data Show Reduced Weight Regain
The results come from the first group of participants with six months of follow-up. In this midpoint cohort of 45 people, 29 received the resurfacing procedure and 16 underwent a sham procedure. All participants had previously lost at least 15% of their body weight using tirzepatide before discontinuing the drug.
On average, patients lost about 40 pounds during GLP-1 therapy. Six months after stopping treatment, those in the control group regained significantly more weight. Participants who had the sham procedure regained about 40% more weight than those who received the actual treatment.
Those who underwent more extensive resurfacing regained only about 7 pounds, maintaining over 80% of their original weight loss. In contrast, the control group regained roughly twice as much. The gap between the groups continued to widen from one to six months after the procedure, suggesting the effect may be durable.
“What’s particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response,” Dr. Sullivan said. “That gives us confidence that we’re targeting the right biology.”
Safety and Recovery
No serious complications were reported from either the device or the procedure. Recovery appears to be quick and straightforward.
“Other than recovering from the general anesthesia, there isn’t much recovery time involved,” Dr. Sullivan said. “You can be back to your daily routine in about a day. Participants could not tell if they had the sham or real procedure because there are not a lot of symptoms after the procedure.”
Why the Gut Plays a Key Role
The procedure targets the small intestine, where hormones influenced by GLP-1 drugs are produced. Over time, diets high in fat and sugar can alter the duodenal mucosal layer, changing how the body responds to food and disrupting hormone signaling. These changes can contribute to insulin resistance and metabolic disease.
By restoring a healthier mucosal lining, the procedure aims to reset metabolism at a lower body weight after stopping medications like Ozempic, helping sustain long-term results.
What Comes Next
Duodenal mucosal resurfacing is still considered investigational. The larger REMAIN-1 study includes more than 300 participants and is fully enrolled and randomized. Researchers expect topline six-month data from the pivotal cohort in early fourth quarter of 2026, followed by a planned marketing submission later that year.
Dr. Sullivan will present the study findings, “Duodenal mucosal resurfacing prevents weight regain after tirzepatide withdrawal: REMAIN-1 multicenter, randomized, double-blind, sham-controlled clinical trial – midpoint cohort results,” abstract 642, at 8:30 a.m. CDT, Monday, May 4.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.